IDEXX(IDXX) Prnewswire·2025-01-23 12:00Core Insights - IDEXX Laboratories, Inc. has launched IDEXX Cancer Dx™, a pioneering diagnostic panel for early detection of lymphoma in dogs, particularly targeting the 20 million dogs at higher risk for cancer in North America [1][2][3] - The test is affordable, costing as low as $15, and provides actionable results within 2–3 days, making it accessible for veterinarians [1][4] - Cancer is a leading cause of death in dogs, with 1 in 4 dogs in the U.S. expected to be diagnosed with cancer in their lifetime, highlighting the critical need for early detection [2][3] Company Overview - IDEXX is recognized as a global leader in pet healthcare innovation, with over 40 years of experience in veterinary research and technology development [3][6] - The company employs approximately 11,000 people and offers solutions in more than 175 countries, indicating a strong global presence [7] - IDEXX Cancer Dx is designed to integrate seamlessly into existing veterinary workflows, enhancing the ability of veterinarians to manage cancer proactively [6][4] Market Demand - A recent survey revealed that 73% of pet owners are interested in cancer screening tests for their pets, indicating a strong market demand for proactive healthcare solutions [2][4] - The IDEXX Cancer Dx panel aims to improve the quality of life for canine cancer patients by enabling earlier clinical diagnoses compared to traditional methods [4][5] Future Plans - IDEXX plans to expand the Cancer Dx panel over the next three years to cover a broader range of canine cancer cases, further transforming cancer detection and intervention [1][3] - The IDEXX Cancer Dx test for canine lymphoma will be available at IDEXX Reference Laboratories in the U.S. and Canada starting in late March 2025 [5][9]